Use of cabazitaxel in treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC): patient characteristics, safety and effectiveness in the FUJI cohort

导出原文传递

翻译打印收藏纠错

作者： Fourrier-Reglat, A. ^[1] ; Oudard, S. ^[2] ; Fizazi, K. ^[3] ; Joly, F. ^[4] ; Tubach, F. ^[5] ; Rouyer, M. ^[6] ; Lamarque, S. ; Guiard, E. ; Balestra, A. ; Lacueille, C. ; Jove, J. ; Droz-Perroteau, C. ; Moore, N.

作者单位： CHU Cote Nacre, Med Oncol Serv, Ctr Francois Baclesse, Caen, France ^[1] Sorbonne Univ, Hop Pitie Salpetriere, AP HP,Ctr Pharmacoepidemiol Cephepi,INSERM,UMR 11, Dept ^[2] Univ Bordeaux, Bordeaux PharmacoEpi, INSERM, CIC1401, Bordeaux, France ^[3] Hop Europeen Georges Pompidou, Med Oncol Serv, Paris, France ^[4] Univ Bordeaux, Bordeaux PharmacoEpi, CIC1401, Bordeaux, France ^[5] Inst Gustave Roussy, Med Oncol Serv, Villejuif, France ^[6]

发布时间 2020-08-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Fundamental & clinical pharmacology.

2018年32卷S1期

60-60页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Use of cabazitaxel in treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC): patient characteristics, safety and effectiveness in the FUJI cohort

Fundamental & clinical pharmacology.

相似文献

Fundamental & clinical pharmacology.

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Use of cabazitaxel in treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC): patient characteristics, safety and effectiveness in the FUJI cohort

Fundamental & clinical pharmacology.

相似文献

Fundamental & clinical pharmacology.

相关期刊

检索历史清除